Related Experiment Video

Updated: Jul 12, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Indications for Cardiac Resynchronization Therapy in Patients with Congenital Heart Disease

Peter P Karpawich1, Henry Chubb2

  • 1Department of Pediatrics, Central Michigan University College of Medicine, Cardiac Electrophysiology, The Children's Hospital of Michigan, Detroit, MI, USA.

Cardiac Electrophysiology Clinics
|October 21, 2023
PubMed

Insights

Congenital heart disease (CHD) causes unique heart failure, differing from elderly causes. Cardiac resynchronization therapy (CRT) offers benefits for CHD patients but faces implantation challenges due to complex anatomy.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Congenital Heart Disease

Background:

  • Heart failure in congenital heart disease (CHD) arises from distinct etiologies compared to age-related heart failure.
  • CHD patients present with congenital structural abnormalities impacting cardiac function.
  • Elderly heart failure is typically linked to aging and acquired cardiovascular conditions.

Purpose of the Study:

  • To explore the unique aspects of heart failure in patients with congenital heart disease.
  • To evaluate the potential benefits and challenges of cardiac resynchronization therapy (CRT) in CHD.
  • To highlight the complexities of CRT implantation in the context of CHD anatomy.

Main Methods:

  • Comparative analysis of heart failure etiologies in CHD versus elderly populations.
  • Review of existing literature on cardiac resynchronization therapy (CRT) application in CHD.
  • Discussion of anatomical and technical challenges in CRT lead placement for CHD patients.

Main Results:

  • Heart failure in CHD is driven by congenital malformations, unlike age-related changes in the elderly.
  • Cardiac resynchronization therapy (CRT) shows potential therapeutic benefits for select CHD patients.
  • CRT implantation in CHD is complicated by intricate cardiac structures and venous access difficulties.

Conclusions:

  • Heart failure management in CHD requires understanding its unique pathophysiology.
  • Cardiac resynchronization therapy (CRT) is a viable option for CHD, but requires specialized approaches.
  • Overcoming anatomical challenges is crucial for successful CRT implementation in congenital heart disease.

Keywords:
Biventricular pacingCardiac resynchronizationConduction system/septal pacingCongenital heart diseaseHeart failure

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.7K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

654

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598